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Abstract 
Background: In traumatic brain injury (TBI) patients desmopressin administration may induce rapid decreases in 
serum sodium and increase intracranial pressure (ICP).
Aim: In an international multi-centre study, we aimed to report changes in serum sodium and ICP after desmopres-
sin administration in TBI patients.
Methods: We obtained data from 14 neurotrauma ICUs in Europe, Australia and UK for severe TBI patients (GCS ≤ 8) 
requiring ICP monitoring. We identified patients who received any desmopressin and recorded daily dose, 6-hourly 
serum sodium, and 6-hourly ICP.
Results: We studied 262 severe TBI patients. Of these, 39 patients (14.9%) received desmopressin. Median length 
of treatment with desmopressin was 1 [1–3] day and daily intravenous dose varied between centres from 0.125 
to 10 mcg. The median hourly rate of decrease in serum sodium was low (− 0.1 [− 0.2 to 0.0] mmol/L/h) with a 
median period of decrease of 36 h. The proportion of 6-h periods in which the rate of natremia correction exceeded 
0.5 mmol/L/h or 1 mmol/L/h was low, at 8% and 3%, respectively, and ICPs remained stable. After adjusting for 
IMPACT score and injury severity score, desmopressin administration was independently associated with increased 
60-day mortality [HR of 1.83 (1.05–3.24) (p = 0.03)].
Conclusions: In severe TBI, desmopressin administration, potentially representing instances of diabetes insipidus is 
common and is independently associated with increased mortality. Desmopressin doses vary markedly among ICUs; 
however, the associated decrease in natremia rarely exceeds recommended rates and median ICP values remain 
unchanged. These findings support the notion that desmopressin therapy is safe.
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Background
Traumatic brain injury (TBI) is the leading cause of 
death and disability in trauma patients [1, 2]. Damage to 
the function of the posterior pituitary gland may cause 
arginine-vasopressin (ADH) deficiency (central diabetes 
insipidus—DI), leading to major water loss and severe 
hypernatremia, an independent risk factor for death [3].
Treatment of DI typically includes desmopressin to 
compensate for antidiuretic hormone (ADH) deficiency, 
and cautious replacement of the free water deficit with 
relatively hypotonic fluid to correct or prevent severe 
hypernatremia. Risk factors for diabetes insipidus (DI) 
in previous studies in TBI patients [4, 5] have included a 
low Glasgow coma scale (GCS) score, cerebral oedema, 
a head abbreviated injury score (AIS) ≥ 3, and fixed 
dilated pupils, replicating factors known to be important 
in defining TBI severity. Thus, those most at risk of DI 
may also be the most vulnerable to changes in osmolarity 
induced by DI and its treatment. Considering this notion, 
several studies have raised concerns as to whether hyper-
natremia itself might be deleterious in severely head-
injured patients [6–9] while others have been concerned 
that too rapid correction of hypernatremia with desmo-
pressin therapy may worsen intracranial hypertension or 
induce demyelinating osmotic shock [10–15].
Despite the above concerns, no multicenter study has 
described the prevalence of desmopressin use in adult 
patients with severe TBI; investigated serum sodium 
and intracranial pressure (ICP) changes after the initia-
tion of desmopressin in severe TBI patients or assessed 
whether there is significant practice variation in the use 
of desmopressin. Accordingly, in an international, multi-
centre cohort study of patients with severe TBI, we 
sought to evaluate serum sodium and intracranial (ICP) 
changes after desmopressin administration. Other objec-
tives were to estimate the prevalence of desmopressin use 
in severe TBI patients and to describe practice variation 
between centres in relation to desmopressin. Specifically, 
we aimed to test the following hypotheses: 1. That rapid 
changes (> 1  mmol/L/h) in sodium levels with desmo-
pressin use would be uncommon; 2. That treatment 
with desmopressin would not be associated with signifi-
cant (> 5 mmHg) increases in median ICP; 3. That > 10% 
of severe TBI patients would require desmopressin 
administration.
Methods
Study population
We performed a retrospective analysis of a dataset from 
14 Intensive Care Units (ICUs) treating TBI patients in 
Australia, the UK and Europe. Ethics approval for contri-
bution to this dataset was obtained locally by each centre 
according to local requirements.
Two centres were from Australia (both from Mel-
bourne), 2 were from the UK (London and Cambridge) 
and the remaining 10 were from continental Europe 
(Paris and Nice, France; Valencia, Spain; Lausanne, Swit-
zerland; Brussels, Belgium; Monza, Italy; Berlin, Ger-
many; Rotterdam, The Netherlands; Solna, Sweden and 
Innsbruck, Austria).
We included the first 20 patients sequentially admit-
ted to each centre in 2015 into the database (except two 
centers that included 14 and 10 patients, respectively). 
Inclusion criteria included age ≥ 18  years, severe TBI 
as defined by a GCS of 8 or less after resuscitation but 
before sedation, and presence of an ICP monitor in place 
for at least 72 h. Patients dying within 48 h of ICU admis-
sion were excluded.
Data collection
Each centre retrospectively collected demographic, 
clinical and biochemical data. Baseline admission data 
included age, sex, weight, brain CT-scan findings as 
required to calculate the Marshall score, and illness 
severity scores (injury severity score (ISS), APACHE-II). 
Centres collected prehospital physiological parameters, 
including GCS after resuscitation, pupil reactivity to 
light, haemoglobin and blood glucose levels, and calcu-
lated an IMPACT-score (core + CT + lab) [16] for each 
patient.
Additional daily data for up to 7 days after ICU admis-
sion included six-hourly ICPs as recorded from the 
external ventricular drain (EVD) or intraparenchymal 
catheter, six-hourly serum sodium from blood gas meas-
urements and daily diuresis. Important aspects of TBI 
care included neurosurgery (clot evacuation, decompres-
sive craniectomy, extra-ventricular drainage), barbiturate 
coma, osmotherapy, the use of therapeutic hypothermia 
(T < 35  °C), and daily total desmopressin administered. 
Finally, outcome data included ICU and hospital mortal-
ity, and ICU and hospital length of stay.
Study variables
We recorded daily total desmopressin dose and 6-hourly 
serum sodium from arterial blood gas analysis for the 
first 7 days of ICU stay. We took the highest sodium level 
on that day to be the serum sodium at the time of desmo-
pressin administration. To calculate the rate of serum 
sodium correction, we analysed the time taken for it to 
reach 145  mmol/L, the upper limit of normal. We also 
recorded 6-hourly serum sodium changes to assess for 
acute changes in natremia after the start of desmopressin. 
Daily urine output and osmotherapy use were recorded. 
To evaluate potential risk factors for severe natremia at 
the time of desmopressin administration, we separated 
the cohort of patients who received desmopressin into 
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two groups according to median natremia at the time 
of desmopressin administration. Missing data on serum 
sodium and ICP were not imputed.
Statistical analysis
We expressed quantitative variables as means (stand-
ard deviation) or medians [interquartile range] accord-
ing to their distribution, while categorical variables were 
expressed as counts (proportion). We compared normally 
distributed variables with the t test and used the Chi-
square test to compare proportions. For non-normally 
distributed variables, we used the Mann–Whitney test.
To compare serum sodium changes over time in 
patients who received and those who did not receive 
desmopressin, we conducted a two-way analysis of vari-
ance (ANOVA), with one within-subjects factor (time) 
and one between-subjects factor (desmopressin or no 
desmopressin). We examined the relationship between 
60-day mortality and desmopressin administration by 
Cox proportional-hazards regression model. We adjusted 
the model for baseline risk of death by including the 
IMPACT score (core + CT + lab) and the Injury Sever-
ity Score (ISS) [17], censoring at the time of hospital 
discharge.
Two-sided level of significance was fixed at 5%. We 
analysed results using R open source software 3.4.1 
(http://www.R-proje ct.org) (The R Foundation for Statis-
tical Computing, Vienna, Austria) and Prism (GraphPad 
software, San Diego, USA).
Results
General characteristics
We collected data on 262 patients. All patients were 
included in the analysis. Characteristics of the patients 
are reported in Table  1. Patients were predominantly 
middle-aged males with a median Injury Severity Score 
(ISS) of 30. One-third had at least one fixed pupil at hos-
pital admission. One-third of patients underwent neuro-
surgery for clot evacuation and a similar proportion had 
a ventricular drain inserted. Overall in-hospital mortality 
was 28%.
Desmopressin administration
Overall, 39 patients (14.9%) received desmopressin at 
any time during the first 7 days of their ICU stay. Patients 
who received desmopressin were younger and had more 
severe TBI than patients who did not, as shown by a 
lower GCS, a greater proportion of patients with fixed 
dilated pupils, more severe Marshall scores, and higher 
APACHE II scores (Table 1). The mortality rate was 41% 
for patients who received desmopressin and 26% for 
those who did not (Table 1, p = 0.04). The median delay 
between ICU admission and first desmopressin admin-
istration was 1 [1–3] day. Figure  1 shows the 6-hourly 
sodium values over the 7 first days of ICU admission in 
patients who received desmopressin and those who did 
not. During this 7-day period, natremia was significantly 
higher in those who received desmopressin.
Table 1 General characteristics and outcomes of patients receiving desmopressin and those not receiving desmopressin
Data are reported as mean ± SD, median [interquartile ranges] or n (proportion)
EVD extraventricular drain, GCS Glasgow Coma Scale, ISS injury severity score, APACHE acute physiology and chronic health evaluation
Variable Total (n = 262) No desmopressin 
(n = 223)
Desmopressin (n = 39) p
Age, years 46 ± 19 48 ± 19 35 ± 13 < 0.001
Weight, kg 76 ± 14 77 ± 14 76 ± 10 0.99
Male, n (%) 202 (77) 168 (75) 34 (87) 0.10
GCS prior to sedation 6 [3–8] 6 [4–8] 3 [3–6] 0.01
Fixed pupils at admission 87 (33) 66 (30) 21 (62) 0.003
Marshall score 3 [2–5] 3 [2–5] 5 [3–5] 0.09
ISS 30 [25–42] 30 [25–42] 31 [25–44] 0.58
APACHE II 20 [15–26] 19 [15–25] 23 [15–37] 0.14
Neurosurgery (clot evacuation), n (%) 94 (36) 76 (34) 18 (46) 0.15
EVD, n (%) 84 (32) 69 (31) 15 (38) 0.35
Extended IMPACT predicted 6 month-mortal-
ity,  %
25 [14–40] 25 [13–39] 28 [17–44] 0.42
Osmotherapy within 7 days, n (%) 140 (53) 125 (56) 28 (72) 0.066
Hospital Mortality, n (%) 63 (24) 57 (26) 16 (41) 0.04
Hospital stay, days 20 [10–31] 20 [12–31] 19 [6–31] 0.14
ICU stay, days 14 [8–21] 14 [9–20] 17 [5–25] 0.74
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Clinical and biochemical data on the day of desmopres-
sin administration are presented in Table  2. Natremia 
was 153 [148–158] mmol/L at the time of desmopres-
sin administration, representing an increase in serum 
sodium of 5 [2–9] mmol/L over the previous 12  h with 
a median urinary output of more than 4  L/24  h, both 
supporting the clinical diagnosis of DI. Additional data 
on daily urine output are provided in Additional file  1: 
Figure S1A. The evolution of serum sodium from 24  h 
before to 72 h after the first desmopressin administration 
is presented in Additional file 1: Figure S1B. The median 
number of days where desmopressin was given was 1 
[1–3] day. Because the use of osmotherapy might affect 
serum sodium level and urine output, two key elements 
for desmopressin treatment, we analyzed the 39 patients 
who received desmopressin according to the use of osmo-
therapy prior to desmopressin intake. Ten patients (26%) 
who received desmopressin also received hypertonic 
saline prior to desmopressin while 71 (32%) of patients 
who did not receive desmopressin were given hypertonic 
saline over the first 7 days of ICU admission. 17 patients 
(44%) who received desmopressin also received man-
nitol prior to desmopressin while 82 (37%) of patients 
who did not receive desmopressin were given mannitol 
over the first 7  days of ICU admission. Together, these 
data suggest that the proportion of patients who received 
osmotherapy was similar among those who received 
desmopressin and those who did not receive it.
The daily intravenous dose of desmopressin varied 
between centres, ranging from 0.125 μg to 10 μg. Single 
desmopressin doses ranged from 0.125 to 2 μg, with 1 
and 2 μg being the most common doses (3 and 5 centers, 
respectively). Daily desmopressin was the highest on the 
first day of administration, with a median total dose of 1 
[0.5–2.0] μg (Fig.  2). The total amount of desmopressin 
received per patient was 2 [1–4] μg over the first 7 days 
in ICU.
The characteristics of serum sodium changes after the 
start of desmopressin treatment are reported in Table 2. 
Of note, the median hourly rate of decrease in serum 
sodium from the time of first desmopressin administra-
tion to the upper value of normal (145 mmol/L) was low 
(− 0.1 [− 0.2 to 0.0] mmol/L/h) with a median period of 
36 h to occur and an overall change of − 3 mmol/L over 
such period (Table  2). Consistent with this, the propor-
tion of 6-hour periods in which the rate of natremia cor-
rection exceeded 0.5  mmol/L/h or 1  mmol/L/h was as 
low, at 8% and 3%, respectively. Moreover, serum sodium 
continued to increase 12 h after desmopressin intake in 
a small proportion of patients (8%), but this proportion 
rose to 26% at 24  h. On average, ICPs remained stable 
over the period of serum sodium correction (Table 2), the 
same was observed when comparing the period before 
and after desmopressin administration (Additional file 1: 
Figure S1C). Individual mean ICPs variations show that 8 
patients increased their mean ICPs of 5 mmHg or more, 
Fig. 1 Natremia during ICU stay according to desmopressin administration status. Red dots = natremia at a given time in patients who received 
desmopressin, Red curve = average natremia over time in patients who received desmopressin. Black dots = natremia at a given time in patients 
who did not receive desmopressin, Black curve = average natremia of patients who did not receive desmopressin. p < 0.001 for natremia over time 
between patients who received desmopressin and those who did not receive desmopressin (two-way ANOVA)
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5 decreased their mean ICPs of 5 mmHg or more and 26 
had variations in mean ICPs lower than 5  mmHg with 
mortality of 38, 40 and 42%, respectively. Moreover, dur-
ing the period when the rate of serum sodium correction 
exceeded 0.5 mmol/L/h (Fig. 3), ICP values remained sta-
ble. As a surrogate marker of intracranial hypertension, 
25 (64%) patients received osmotherapy after desmo-
pressin compared with 125 (56%) in those not receiving 
desmopressin (p = 0.35).
Because the use of osmotherapy might affect the rate 
of serum sodium correction as well as the evolution of 
ICPs after desmopressin administration, we analyzed 
the 39 patients who received desmopressin according to 
the use of osmotherapy from the first day desmopressin 
was given. Those patients receiving osmotherapy dur-
ing desmopressin therapy (n = 25) had a median change 
in serum sodium of − 0.06 mmol/L/h [− 0.18 to +0.07], 
while those not receiving osmotherapy (n = 14) had a 
median change in serum sodium of − 0.17  mmol/L/h 
[− 0.27 to 0.00]. There was no significant difference 
between the two groups (p = 0.20). The proportion of 
6-h periods in which the rate of serum sodium correc-
tion exceeded 1 mmol/L/h was 2.7% (7 in 262) for those 
receiving osmotherapy whereas it was 5.0% (4 in 79) in 
those not receiving osmotherapy (p = 0.49). With regards 
to ICP changes after desmopressin administration, the 
Table 2 Clinical and biochemical data before desmopressin administration, at the time of desmopressin administration 
and after starting desmopressin
ICP intracranial pressure. Data are reported as median [interquartile ranges] or n (proportion)
a Time to reach a natremia of 145 mmol/L or last natremia before loss of follow-up (death or 7 days)
b The change in natremia was calculated as the difference between natremia the day desmopressin was given and the lowest natremia after the start of treatment 
(censored by death, loss of follow-up or natremia of 145 mmol/L)
c Rate of natremia correction was assessed 6 hourly meaning that we screened 341 6-h time periods in 39 patients receiving desmopressin
d The maximum ICP 24 h before desmopressin was compared to the maximum ICP 24 h after desmopressin
Variable Value
Before desmopressin administration
 Natremia 24 h preceding desmopressin, mmol/L 145 [141–150]
 Natremia 12 h preceding desmopressin, mmol/L 147 [143–152]
Day of desmopressin administration
 Natremia, mmol/L 153 [148–158]
 Increase in natremia (compared to 24 h prior), mmol/L 7 [4–12]
 Increase in natremia over 12 h preceding diagnosis, mmol/L 5 [2–9]
 24-h diuresis, mL 4430 [3506–5317]
 24-h urine output, mL/kg/h 2.5 [2.0–2.9]
Desmopressin use
 Number of days with desmopressin 1 [1–3]
 1st day desmopressin dose, μg 1 [0.5–2.0]
 Total desmopressin dose, μg 2 [1–4]
Natremia changes after desmopressin
 Proportion of patients with natremia corrected down to 145 mmol/L, n (%) 23 (59)
 Time to normalize natremia,  hoursa 36 [12–86]
 Change in natremia after treatment, mmol/Lb − 3 [− 9 to 0]
 Rate of change of natremia after treatment, mmol/L/h − 0.1 [− 0.2 to 0.0]
Fast correction of hypernatremia
 Proportion of time with > 0.5 mmol/L/hr decrease in natremia, n (%)c 31/341 (9%)
 Proportion of time with > 1 mmol/L/hr decrease in natremia, n (%)c 11/341 (3%)
Worsening of hypernatremia
 Patients with natremia increase 12 h after starting desmopressin, n (%) 3/39 (8%)
 Patients with natremia increase 24 h after starting desmopressin, n (%) 10/39 (26%)
Effect of natremia changes on ICP
 Change in mean ICP after 24 h, mmHg 0 [− 3 to + 4]
 Change in maximum ICP,  mmHgd 0 [− 8 to + 11]
 Use of osmotherapy in the 48 h following desmopressin, n (%) 12 (31)
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median ICP difference was 0.0  mmHg [− 6.8 to 4.3] in 
those who received osmotherapy, while it was 0.0 mmHg 
[− 3.0 to 3.5] in those who did not (p = 0.68).
When patients who received desmopressin were sepa-
rated into two groups according to serum sodium levels 
below or above the median at the time of desmopressin 
administration (Table  3), those with combined desmo-
pressin and marked hypernatremia (> 153 mmol/L) were 
threefold more likely to have received osmotherapy on 
the same day.
Desmopressin administration and outcome
Unadjusted survival analysis according to desmopressin 
use showed a significant difference in mortality between 
patients who received desmopressin and those who did 
not (p = 0.02). After adjusting for IMPACT score and ISS 
in a Cox proportional hazards model to predict mortality 
at 60 days, desmopressin use was independently associ-
ated with increased mortality with a hazard ratio of 1.83 
(1.05–3.24) (p = 0.03).
Discussion
Key findings
In a multi-centre international study, we aimed to eval-
uate changes in serum sodium and intracranial (ICP) 
changes after desmopressin therapy. Moreover, we aimed 
to estimate the prevalence of desmopressin use in severe 
TBI patients and describe practice variation between 
centres in relation to desmopressin dose. We found that 
the rate of change in natremia was very low and rarely 
exceeded the recommended rate. Moreover, during such 
correction, median ICP values remained unchanged and 
there was no increase in the use of osmotherapy. Finally, 
we found that desmopressin was used in approximately 
one in every seven patients, that the dose of desmopres-
sin used could vary more than tenfold from one centre 
to another and that desmopressin administration was an 
independent predictor of mortality.
Relationship with previous studies
Previous studies in this area have looked at diabetes 
insipidus rather than desmopressin use. The focus of 
the study was the use of desmopressin and its effects on 
serum sodium and ICP variations in TBI patients. Clini-
cians used desmopressin based on clinical judgment and 
biochemical variables. Such use of desmopressin does 
not imply accuracy of diagnosis but allows an assessment 
of desmopressin’s effects on serum sodium and ICP in 
clinical practice. While desmopressin use does not neces-
sarily reflect diabetes insipidus, in our study, all patients 
receiving desmopressin had a serum sodium level greater 
or equal to 143 mmol/L and 29 of them had a 24-h diu-
resis greater than 3500 mL. These constitute 2 major cri-
teria of DI [18], and as such, we believe that almost all 
administration of desmopressin reflected true DI. Unlike 
the classical definition that looks at 24-h diuresis, in the 
ICU setting, desmopressin treatment may have been ini-
tiated early in some patients from our cohort, preventing 
the 24-h diuresis from exceeding 3500  mL. Moreover, 
Fig. 2 Median daily desmopressin dose in patients who received 
desmopressin. Boxplot represents median, quartiles and minimum/
maximum values
Fig. 3 Intracranial pressure changes after a natremia correction rate 
higher than 0.5 mmol/L/h (during 6 h). The red boxplots correspond 
to the median ICPs and interquartile ranges at the start and at the 
end of the six-hour period (three patients with raised ICPs of 37, 43 
and 73 mmHg at time 0 increased their ICPs up to 59, 54 and 100, 
respectively, 6 h after. They died early at day 2, 3 and 4, respectively, 
suggesting their DI was related to brain death)
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the use of osmotherapy in patients who received desmo-
pressin was similar to the use of osmotherapy in patients 
who did not receive desmopressin, making exposure to 
osmotherapy-induced hypernatremia and polyuria com-
parable. In addition, our finding of a likely DI prevalence 
of 14.9% is in accordance with previous studies, that have 
reported that 15–29% of patients develop DI in ICU post 
TBI [3–5, 19–22]. This variability in the prevalence of DI 
is likely due to the variability of criteria used for DI diag-
nosis; the severity of TBI amongst the studied cohorts, 
and the timing of DI assessment. Further studies are nec-
essary to better assess pituitary function at the bedside 
and more accurately diagnose DI patients to better tar-
get those having a true lack of AVP secretion. This would 
benefit from the rapid measurement of plasma copeptin 
[23, 24], a precursor-derived peptide of ADH, to allow 
rapid and targeted desmopressin therapy.
As shown, desmopressin is a relatively common ther-
apy in TBI patients. However, there are no guidelines 
regarding its dosage for DI. In non-ICU patients with 
DI, intravenous doses of 0.125–0.5 μg have very simi-
lar effects on diuresis and urine concentration and with 
a suggested dose–response ceiling effect at 0.25 μg and 
lasting for 7–12 h [25]. However, at a dose of 0.5 μg, the 
duration of action is consistently longer (11  h) [25]. In 
the ICU setting, a recent review article recommended 
that desmopressin doses of 0.5–1 μg may be appropriate 
initially [26]. We found, however, that daily doses of 
desmopressin varied significantly (from 0.125 to 10 μg) 
highlighting the variation of practice among centres.
A safe rate of natremia correction as low as 0.5 mmol/
L/h has been proposed [26] when treating DI in severely 
head-injured patients due to the fact that these patients 
generally have raised or borderline ICPs. However, to 
our knowledge, detailed data of clinician practice in 
this respect are lacking. In our study, the average rate of 
natremia correction was low, only occasionally exceed-
ing 0.5  mmol/L/h and exceptionally exceeding 1  mmol/
L/h. Thus, the median ICP remained stable during DI 
treatment, even when the rate of correction exceeded 
0.5  mmol/L/h. Moreover, there was no increased need 
for osmotherapy use after desmopressin use (compared 
to patients who were not given desmopressin), implying 
that desmopressin administration did not lead to more 
episodes of intracranial hypertension. These observations 
support the safety of desmopressin in this setting.
In TBI patients with DI, mortality has been reported 
between 33 and 74% with even higher mortality (close to 
90%) in those developing DI within 72 h of ICU admis-
sion [27]. With 42% of in-hospital mortality in patients 
who received desmopressin, our study is consistent with 
the above studies. A higher mortality for early desmo-
pressin administration was not obvious in our cohort 
but this may be related to the exclusion of patients dying 
Table 3 Characteristics of  patients according to  the  severity of  hypernatremia at  the  time of  desmopressin 
administration
Data are reported as mean ± SD, median [interquartile ranges] or n (proportion)
APACHE acute physiology and chronic health evaluation, desmo desmopressin, ICP intracranial pressure, IMPACT international mission for prognosis and analysis of 
clinical trials in TBI, ISS injury severity score
Na ≤ 153 mmol/L
n = 20
Na > 153 mmol/L
n = 19
p
Age, years 35 ± 9 34 ± 17 0.823
Weight, kg 77.0 ± 11 75 ± 10 0.599
Male, n (%) 18 (90) 16 (84) 0.661
ISS 30 [25–41] 32 [25–46] 0.722
Natremia 12 h before desmopressin 143 [139–145] 152 [150–155] < 0.001
Natremia increase over the last 12 h before desmopressin 4 [2–6] 6 [5–9] 0.07
Natremia at the time of desmopressin 148 [145–149] 158 [155–161] –
Mean ICP (1st day desmo), mmHg 18 ± 13 18 ± 8 0.206
Max ICP (1st day desmo), mmHg 23 ± 17 24 ± 11 0.325
Any Osmotherapy 1st day desmo, n (%) 4 (20) 14 (74) 0.001
Mannitol, n (%) 2 11 –
Hypertonic saline, n (%) 2 5 –
Fixed pupils at admission, n (%) 10 (50) 11 (58) 0.751
Diuresis, mL 4638 [3520–5385] 4397 [3595–5240] 0.491
APACHE II 20 [14–40] 23 [20–33] 0.599
IMPACT predicted 6-month mortality 25 [17–43] 30 [19–44] 0.623
Mortality, n (%) 7 (35) 9 (47) 0.433
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within the first 48  h from database, thereby excluding 
those having early DI. Despite this, we report a median 
time to desmopressin administration of 1  day, similar 
to previous studies on diabetes insipidus. On univariate 
analysis, we found that higher baseline natremia (12  h 
before desmopressin administration) and osmotherapy 
given the same day were risk factors for severe hyperna-
tremia at the time of desmopressin administration. We 
hypothesize that osmotherapy is a confounding factor 
that may mimic and delay DI diagnosis due to osmoth-
erapy-related expected diuresis (mannitol) or expected 
hypernatremia (hypertonic saline).
Survival analysis demonstrated that DI, as assessed 
by desmopressin use, remains independently associ-
ated with mortality after adjustment for baseline risk of 
death including complete IMPACT score (core + CT 
score + lab) and injury severity score, the latter account-
ing for extracerebral traumatic injuries [17]. Thus, DI is 
also a surrogate marker for the severity of brain injury.
Implications of study findings
Our findings imply that, in TBI patients, desmopressin 
can be safely administered when DI is strongly suspected. 
Moreover, they imply that clinicians should be aware 
that osmotherapy may lead to delays in desmopressin 
administration, possibly by also causing polyuria and 
hypernatremia. Finally, they imply that the dosing of this 
intervention remains highly variable.
Strengths and limitations
Our study has several strengths. It is the largest multi-
centre study of this condition to date and the only 
international one. It provides detailed data on practice 
variation in relation to dose of desmopressin use. It also 
provides clinically relevant data on changes in natremia, 
osmotherapy, and ICP after desmopressin therapy. 
Finally, the findings have clinical implications.
This study has some limitations. This is a retrospec-
tive study with the inherent limitations of such stud-
ies. However, the data are detailed, numerical in nature 
and not subject to selection bias. Moreover, we may 
have missed patients with milder or transient DI who 
did not receive desmopressin and, therefore, may have 
underestimated DI incidence. Nonetheless, we aimed 
to describe serum sodium changes after treatment with 
desmopressin to assess its safety in terms of rate of 
change in natremia and ICP. We did not record details 
of uremia, liver failure or antiplatelet use that might 
have also been less common indications for the use of 
desmopressin. We cannot exclude that a few patients 
received desmopressin given in the operating room, 
and then at higher doses. However, we consider this 
unlikely. By recording natremia 6-hourly only, we may 
have missed more extreme natremia measurements, 
however, previous DI studies have mostly only reported 
once-daily serum sodium. Thus, our observations are 
markedly more detailed than previous studies and the 
only ones to provide information on the rate of changes 
in natremia and ICP.
Conclusions
In summary, desmopressin administration appears 
to occur in approximately one in every seven patients 
after severe TBI and is independently associated with 
increased mortality. However, the dose of desmopres-
sin used varies markedly from one center to another. 
Despite such variability, the median rate of change in 
natremia after such treatment is low. Moreover, such 
rate of change rarely exceeded the recommended rate. 
Finally, after desmopressin therapy, median ICP values 
remain unchanged. In their aggregate, these findings 
support the notion that, in severe TBI patients with 
clinical suspicion of DI, desmopressin therapy is patho-
physiological rational and safe.
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